Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
AVXS's Cash-to-Debt is ranked higher than
64% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. AVXS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
AVXS' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
AVXS's Interest Coverage is ranked higher than
52% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AVXS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
AVXS' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Altman Z-Score: 62.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -51.19
AVXS's ROE % is ranked lower than
55% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. AVXS: -51.19 )
Ranked among companies with meaningful ROE % only.
AVXS' s ROE % Range Over the Past 10 Years
Min: -140.56  Med: -97.65 Max: -51.19
Current: -51.19
-140.56
-51.19
ROA % -47.42
AVXS's ROA % is ranked lower than
60% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. AVXS: -47.42 )
Ranked among companies with meaningful ROA % only.
AVXS' s ROA % Range Over the Past 10 Years
Min: -807.09  Med: -243.88 Max: -47.42
Current: -47.42
-807.09
-47.42
ROC (Joel Greenblatt) % -547.66
AVXS's ROC (Joel Greenblatt) % is ranked lower than
53% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. AVXS: -547.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AVXS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -109850  Med: -66010.99 Max: -547.66
Current: -547.66
-109850
-547.66
GuruFocus has detected 1 Warning Sign with AveXis Inc $AVXS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AVXS's 30-Y Financials

Financials (Next Earnings Date: 2017-11-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

AVXS Guru Trades in Q3 2016

Paul Tudor Jones 13,500 sh (New)
Jim Simons 53,900 sh (+824.37%)
» More
Q4 2016

AVXS Guru Trades in Q4 2016

Steven Cohen 540,400 sh (New)
Paul Tudor Jones Sold Out
Jim Simons 42,300 sh (-21.52%)
» More
Q1 2017

AVXS Guru Trades in Q1 2017

Andreas Halvorsen 381,626 sh (New)
Steven Cohen 717,514 sh (+32.77%)
Jim Simons Sold Out
» More
Q2 2017

AVXS Guru Trades in Q2 2017

Andreas Halvorsen 893,258 sh (+134.07%)
Steven Cohen 905,667 sh (+26.22%)
» More
» Details

Insider Trades

Latest Guru Trades with AVXS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:SRPT, NAS:LGND, NAS:ONCE, NAS:PTLA, NAS:AGIO, NAS:LOXO, NAS:BPMC, NAS:FOLD, NAS:HALO, NAS:NKTR, NAS:SAGE, NYSE:XON, NAS:FGEN, NAS:RARE, NAS:INSM, NAS:CORT, NAS:CLVS, NAS:PBYI, NAS:ARRY, NAS:RGEN » details
Traded in other countries:AX4.Germany,
Headquarter Location:USA
AveXis Inc is a clinical-stage gene therapy company. It is engaged in developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its product candidate is AVXS-101.

AveXis Inc is a United States-based clinical-stage gene therapy company. It is engaged in developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its product candidate, AVXS-101, is a gene therapy product candidate in Phase 1 clinical trial for the treatment of spinal muscular atrophy, or SMA, Type 1, the genetic cause of infant mortality. AVXS-101 is designed to deliver a fully functional human survival motor neuron gene into the nuclei of motor neurons that then generates an increase in survival motor neuron protein levels. The company believes this will result in improved motor neuron function and patient outcomes.

Ratios

vs
industry
vs
history
PB Ratio 6.66
AVXS's PB Ratio is ranked lower than
83% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. AVXS: 6.66 )
Ranked among companies with meaningful PB Ratio only.
AVXS' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 12.2
Current: 6.66
0
12.2
EV-to-EBIT -18.68
AVXS's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. AVXS: -18.68 )
Ranked among companies with meaningful EV-to-EBIT only.
AVXS' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.42  Med: 0 Max: 0
Current: -18.68
-31.42
0
EV-to-EBITDA -18.79
AVXS's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. AVXS: -18.79 )
Ranked among companies with meaningful EV-to-EBITDA only.
AVXS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31.52  Med: 0 Max: 0
Current: -18.79
-31.52
0
Current Ratio 15.62
AVXS's Current Ratio is ranked higher than
74% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. AVXS: 15.62 )
Ranked among companies with meaningful Current Ratio only.
AVXS' s Current Ratio Range Over the Past 10 Years
Min: 0.35  Med: 10.37 Max: 15.62
Current: 15.62
0.35
15.62
Quick Ratio 15.62
AVXS's Quick Ratio is ranked higher than
75% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. AVXS: 15.62 )
Ranked among companies with meaningful Quick Ratio only.
AVXS' s Quick Ratio Range Over the Past 10 Years
Min: 0.35  Med: 10.37 Max: 15.62
Current: 15.62
0.35
15.62

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 7.55
AVXS's Price-to-Net-Cash is ranked lower than
68% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. AVXS: 7.55 )
Ranked among companies with meaningful Price-to-Net-Cash only.
AVXS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.52  Med: 6.43 Max: 11.79
Current: 7.55
4.52
11.79
Price-to-Net-Current-Asset-Value 7.37
AVXS's Price-to-Net-Current-Asset-Value is ranked lower than
69% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. AVXS: 7.37 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
AVXS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.47  Med: 6.28 Max: 11.33
Current: 7.37
4.47
11.33
Price-to-Tangible-Book 6.66
AVXS's Price-to-Tangible-Book is ranked lower than
76% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. AVXS: 6.66 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AVXS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.26  Med: 5.66 Max: 9.51
Current: 6.66
4.26
9.51
Earnings Yield (Greenblatt) % -5.35
AVXS's Earnings Yield (Greenblatt) % is ranked higher than
61% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. AVXS: -5.35 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AVXS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1680.15  Med: 0 Max: 0
Current: -5.35
-1680.15
0

More Statistics

EPS (TTM) $ -4.93
Short Percentage of Float23.94%
52-Week Range $38.46 - 99.45
Shares Outstanding (Mil)31.93

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 60 171 519
EPS ($) -6.11 -5.51 -3.36 3.29
EPS without NRI ($) -6.11 -5.51 -3.36 3.29
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for AVXS

Headlines

Articles On GuruFocus.com
AveXis Reports Second Quarter 2017 Financial and Operating Results Aug 10 2017 
AveXis to Report Second Quarter 2017 Financial and Operating Results Aug 03 2017 
AveXis Announces Pricing of Public Offering of Common Stock Jun 20 2017 
AveXis Announces Proposed Public Offering of Common Stock Jun 19 2017 
AveXis Announces Alignment with FDA on GMP Commercial Manufacturing Process for AVXS-101 Jun 14 2017 
REGENXBIO and AveXis Announce New Exclusive Worldwide Licenses for the Treatment of Two Rare Neurolo Jun 07 2017 
AveXis and REGENXBIO Announce New Exclusive Worldwide Licenses for the Treatment of Two Rare Neurolo Jun 07 2017 
AveXis Reports First Quarter 2017 Financial and Operating Results May 11 2017 
AveXis to Report First Quarter 2017 Financial and Operating Results May 04 2017 
AveXis Presents Results from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the Am Apr 25 2017 

More From Other Websites
Edited Transcript of AVXS earnings conference call or presentation 10-Aug-17 8:30pm GMT Sep 15 2017
Breaking Down Barclays' New Bullish Calls On Biotech Sep 07 2017
AveXis reports 2Q loss Aug 10 2017
AveXis Reports Second Quarter 2017 Financial and Operating Results Aug 10 2017
[$$] Zinsli's Take: Biotech's Saviors Keep Up VCs' Hopes Aug 09 2017
AveXis to Report Second Quarter 2017 Financial and Operating Results Aug 03 2017
AveXis Inc.: Buy at the High? Jul 18 2017
3 Stocks at All-Time Highs Still Worth Buying Jul 08 2017
4 Reasons the AveXis Inc. Rally Could Continue Jul 01 2017
3 Stocks You Probably Never Heard Of Could Catch Fire Soon Jun 22 2017
AveXis (AVXS) Jumps: Stock Rises 7.1% Jun 22 2017
Biotech Movers: AveXis, Clovis, Epizyme Jun 20 2017
AveXis (AVXS) Surges: Stock Moves 5% Higher Jun 19 2017
Top Gainers in the Healthcare Sector: May 22–26, 2017 May 31 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}